Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Core Viewpoint - Qualigen Therapeutics, Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $3.47 million for various corporate purposes [1][3]. Group 1: Offering Details - The company offered 14,724,058 shares of common stock at a price of $0.13 per share and pre-funded warrants to purchase up to 11,972,754 shares at a price of $0.129 per share [1]. - The pre-funded warrants are exercisable upon issuance and will remain exercisable until fully exercised [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for operations and general corporate purposes, including: - Accelerated payment of a $2 million Senior Note issued in July 2024 [3]. - Advancement of clinical trials and preclinical studies [3]. - General working capital [3]. - Possible expansion of the relationship with Marizyme, Inc. under a Co-Development Agreement [3]. - Potential future acquisitions [3]. Group 3: Regulatory Information - The securities were offered under a registration statement on Form S-1, which became effective on September 4, 2024 [4]. - The offering was conducted only by means of a prospectus that is part of the effective registration statement [4].